• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
NTI
Click for more information
0.00% 9.0¢

NEUROTECH INTERNATIONAL LIMITED - Charts / Financials

Market Cap $82.56M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare Medical Devices

Neurotech International Limited is an Australia-based clinical-stage biopharmaceutical... Neurotech International Limited is an Australia-based clinical-stage biopharmaceutical development company. The Company is focused on the development and commercialization of neurological solutions focused predominately on pediatric neurological disorders. The Company conducts clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its NTI/Dolce cannabis strains. It is also commercializing Mente, a home therapy to increase engagement and improve relaxation in autistic children with elevated delta-band brain activity. Its product, Mente Autism, assists with the management of children with autism spectrum disorder (ASD). Its development program NTI164 completed a Phase I/II clinical trial to treat patients with autism spectrum disorder (ASD). Mente Autism is a portable, electroencephalographic (EEG) medical device for home use in the form of a headband that uses closed-loop neurofeedback to helo-relax the minds of children with ASD. More

refresh Created with Sketch. REFRESH
Last update - 15.49pm 26/04/2024 (20 minute delay) ?
Day
Open 8.9¢   Day High 9.0¢   Day Low 8.7¢
Daily Volume 1439697
Bids   Sellers
Number Price Volume   Number Price Volume
1 8.9¢ 18916   7 9.0¢ 236884

Directors & Senior Management

Dr. Alexandra Andrews Chief Operating Officer
Dr. Thomas Duthy Executive Director
Mr. Gerald Quigley Director of Public Relations, Non-Executive Director
Mrs. Erlyn Dawson Joint Company Secretary
Ms. Alessandra Gauvin Joint Company Secretary
Mr. Mark Davies Non-Executive Chairman of the Board
Mr. Robert Maxwell Johnston Non-Executive Director

Data source: Refinitiv

(20min delay)
Last
9.0¢ 		Change
0.000(0.00%) 		Mkt cap ! $82.56M
Open High Low Value Volume
8.9¢ 9.0¢ 8.7¢ $126.8K 1.439M

Buyers (Bids)

No. Vol. Price($)
1 18916 8.9¢
 

Sellers (Offers)

Price($) Vol. No.
9.0¢ 236884 7
View Market Depth
Last trade - 16.10pm 26/04/2024 (20 minute delay) ?
Last
8.9¢ 		  Change
0.000 ( 1.11 %)
Open High Low Volume
8.8¢ 9.0¢ 8.7¢ 178950
Last updated 15.49pm 26/04/2024 ?

Top Stories

Are there gains to be made with the grocery giants?

There is a growing storm of controversy around Coles (ASX:COL) and Woolworths (ASX:WOW) as they face intense scrutiny over price hikes and supplier pressures in a Senate inquiry. This raises an interesting question as to whether investors should cut ties with these corporate giants or wheth...
Raiden’s jump into lithium territory in WA’s Pilbara echoes earlier journey by Azure In its bid to define a noteworthy lithium deposit in WA’s Pilbara region, Raiden Resources is following in the footsteps of another explorer.
Crypto world awaits overnight Bitcoin halving event The four-yearly Bitcoin halving is set to happen in the early hours of tomorrow morning (Saturday, April 20) - it's an event that industry leader Swyftx likened to 'the Olympic Games for the crypto industry'.
1970s on repeat, but there's a silver lining! ABBA fans across Australia know that the 1970s were not only about nervous shuffles to the strains of Dancing Queen, across the linoleum floor at the local Blue Light Disco. Oil had only recently begun to rise, and so synthetic fabrics, like polyester, were very popular. So was central heating, using fuel oil. This is all ancient history now and it would not matter except for the fact that history is now rhyming so hard.
Recce Pharmaceuticals up 6% on new antibiotic production milestone Recce Pharmaceuticals (ASX:RCE) is trading up more than 6 per cent after producing a 5000-dose batch of its new antibiotic RECCE 327 (R327) under Good Manufacturing Practises (GMP) standards.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.